Revaxis SPC: Uses, Safety, Storage and FAQs
Quick summary Revaxis is a vaccine used to help protect against diphtheria, tetanus and poliomyelitis. It has been used as a booster vaccine, mainly in adults, and in some children under specific guidance. This...
This content is for educational purposes only and does not replace medical advice, diagnosis or treatment from a qualified healthcare professional.
Quick summary
Revaxis is a vaccine used to help protect against diphtheria, tetanus and poliomyelitis. It has been used as a booster vaccine, mainly in adults, and in some children under specific guidance. This page summarises the key SPC-style information, including use, administration, storage, side effects and practical safety points.
Medical disclaimer: This article is for general information only and does not replace the official product leaflet, a clinician’s advice, or local immunisation guidance. Vaccination decisions should be made with a qualified healthcare professional.
What Revaxis is used for
Revaxis is a suspension injectable in a pre-filled syringe used to help protect against three serious diseases: diphtheria, tetanus and poliomyelitis.
It has been described as a booster vaccine, especially for adults, and may also be used in children aged 6 to 13 years under specific guidelines.
These diseases can have severe consequences. Diphtheria can affect breathing, tetanus can cause painful muscle stiffness, and poliomyelitis can lead to paralysis.
Important availability note
According to the source content, Revaxis will no longer be available after 1 July 2024. If vaccination is being considered, a healthcare professional can confirm the most appropriate current option and local availability.
Before using Revaxis
Before vaccination, it is important to review any relevant medical history with a healthcare professional.
- Allergy history: Do not use if there is a known hypersensitivity to any component of the vaccine.
- Current illness: If you are unwell or have an ongoing health condition, medical advice should be sought before vaccination.
- Previous reactions: Any prior reaction to a vaccine should be discussed before another dose is given.
The official leaflet and a clinician can help confirm whether the vaccine is suitable in a particular situation.
How Revaxis is given
Revaxis is administered by intramuscular injection, typically in the upper arm.
It should be given by a healthcare professional using standard injection procedures. After vaccination, a short period of observation is commonly used to watch for any immediate reaction.
Possible side effects
Like all vaccines, Revaxis may cause side effects. The source content notes the following:
- soreness at the injection site
- mild fever
- fatigue
These effects are usually mild and short-lived.
Rarely, more serious allergic reactions can occur. Warning signs may include difficulty breathing, swelling of the face or throat, or a rapid heartbeat. Urgent medical help is needed if these occur.
How Revaxis should be stored
Correct storage helps maintain vaccine quality.
- Store in a refrigerator at 2°C to 8°C.
- Do not freeze.
- Keep in the original packaging until use.
- Protect from direct sunlight.
- Check the expiry date before use.
Any expired or improperly stored vaccine should be handled according to local disposal rules.
Composition
The source content states that Revaxis contains inactivated components of diphtheria and tetanus toxins, together with poliovirus components.
It also includes other ingredients such as stabilisers and preservatives to help maintain the product during storage and administration.
If you have concerns about allergies or sensitivities, the full ingredient list in the official leaflet should be checked with a pharmacist or doctor.
Indications and practical recommendations
Revaxis is mainly described as a booster vaccination for adults who have completed their primary immunisation series and need periodic reinforcement of protection.
For children aged 6 to 13 years, use may be considered under specific medical guidance.
The source content also notes that, because Revaxis is no longer available after 1 July 2024, healthcare professionals may consider alternatives such as Repevax or Boostrixtetra where appropriate.
At a glance
| Topic | Key point |
|---|---|
| Protection | Diphtheria, tetanus and poliomyelitis |
| Main use | Booster vaccination |
| Administration | Intramuscular injection |
| Storage | Refrigerated at 2°C to 8°C; do not freeze |
| Availability note | No longer available after 1 July 2024, per source content |
Frequently asked questions
▸ What is Revaxis for?
Revaxis is used to help protect against diphtheria, tetanus and poliomyelitis. It is mainly described as a booster vaccine.
▸ Is Revaxis used for pertussis?
No. The source content states that Revaxis is not designed to protect against pertussis. A healthcare professional can advise on vaccines that include pertussis protection if needed.
▸ What side effects can happen after the shot?
The source content lists soreness at the injection site, mild fever and fatigue as common effects. Severe allergic reactions are rare but need urgent medical attention.
▸ How is Revaxis given?
It is given as an intramuscular injection, usually in the upper arm, by a healthcare professional.
▸ How should Revaxis be stored?
It should be kept refrigerated at 2°C to 8°C, not frozen, and protected from direct sunlight until use.
▸ Is Revaxis still available?
The source content says Revaxis will no longer be available after 1 July 2024. A clinician or pharmacist can confirm current alternatives.
Safety reminder
If you are considering vaccination, always check the official leaflet and speak with a qualified healthcare professional about suitability, allergies, previous reactions and current availability. Seek urgent help for any signs of a severe allergic reaction after vaccination.
Medical disclaimer
This content is for educational purposes only. It should not be used as a substitute for professional medical advice, diagnosis or treatment. Always ask a doctor, pharmacist or qualified healthcare professional before starting, stopping or changing any medicine.
Sources and verification
The following sources or official references are listed to support verification of the medicine information discussed in this article.
- Revaxis Summary of Product Characteristics (SPC)
- UK vaccine guidance and immunisation information
- NHS vaccines information
- European Medicines Agency medicines information
To improve this article with specific references, add a custom field named _aio_sources in the post editor and write one source per line using: Source title|Source URL.
Medicine information can change and may vary depending on country, product formulation, patient history and professional guidance. Always check official medicine information and ask a healthcare professional for personal medical questions.